Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07246447Active, not recruiting
Randomised trial of ketamine and dexmedetomidine in class III obesity (2 arms), sponsored by Cairo University. Primary endpoint: Total nalbuphine consumption at 24 hours. Started Nov 2025; status: active, not recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07246447.